Search hospitals > California > San Diego
Therapeutics Clinical Research
Claim this profileSan Diego, California 92123
Global Leader in Plaque Psoriasis
Global Leader in Psoriasis
Conducts research for Vasculopathic Skin Disease
Conducts research for Atopic Dermatitis
Conducts research for Eczema
98 reported clinical trials
1 medical researcher
Summary
Therapeutics Clinical Research is a medical facility located in San Diego, California. This center is recognized for care of Plaque Psoriasis, Psoriasis, Vasculopathic Skin Disease, Atopic Dermatitis, Eczema and other specialties. Therapeutics Clinical Research is involved with conducting 98 clinical trials across 68 conditions. There are 1 research doctors associated with this hospital, such as Neal D Bhatia.Top PIs
Clinical Trials running at Therapeutics Clinical Research
Plaque Psoriasis
Psoriasis
Cutaneous T-Cell Lymphoma
Mycosis Fungoides
Basal Cell Carcinoma
Atopic Dermatitis
Chronic Urticaria
Lymphoma
Mycosis Fungoides/Sezary Syndrome
Hematological Tumors
TAK-279
for Psoriasis
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.
Recruiting2 awards Phase 31 criteria
ESK-001
for Psoriasis
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.
Recruiting1 award Phase 31 criteria
ESK-001
for Plaque Psoriasis
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study. Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis. Patients must consent and agree to: * ensure drug daily compliance until end of study or discontinuation. * visit the clinic for checkups and assessments. * provide blood and urine samples.
Recruiting1 award Phase 31 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Therapeutics Clinical Research?
Therapeutics Clinical Research is a medical facility located in San Diego, California. This center is recognized for care of Plaque Psoriasis, Psoriasis, Vasculopathic Skin Disease, Atopic Dermatitis, Eczema and other specialties. Therapeutics Clinical Research is involved with conducting 98 clinical trials across 68 conditions. There are 1 research doctors associated with this hospital, such as Neal D Bhatia.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.